Abstract
OBJECTIVES: For effective health care provision, knowledge of disease prevalence is paramount. There has been no systematic endeavour to establish continent-based AS estimates, however, prevalence is thought to vary by country and background HLA-B27 prevalence. This study aimed to estimate AS prevalence worldwide and to calculate the expected number of cases.
METHODS: A systematic literature search was conducted. Prevalence data were extracted and used to calculate the mean prevalence by continent and the expected number of cases based on country-specific prevalence (or, if missing, the prevalence from neighbouring countries). A second estimate was made using the prevalence from countries with similar HLA-B27 prevalences if a country-specific prevalence estimate was not available.
RESULTS: The mean AS prevalence per 10,000 (from 36 eligible studies) was 23.8 in Europe, 16.7 in Asia, 31.9 in North America, 10.2 in Latin America and 7.4 in Africa. Additional estimates, weighted by study size, were calculated as 18.6, 18.0 and 12.2 for Europe, Asia and Latin America, respectively. There were sufficient studies to estimate the number of cases in Europe and Asia, calculated to be 1.30-1.56 million and 4.63-4.98 million, respectively.
CONCLUSION: This study represents the first systematic attempt to collate estimates of AS prevalence into a single continent-based estimate. In addition, the number of expected cases in Europe and Asia was estimated. Through reviewing the current literature, it is apparent that the continuing conduct of epidemiological studies of AS prevalence is of great importance, particularly as diagnostic capabilities improve and with the recent development of the criteria for axial SpA.
| Original language | English |
|---|---|
| Pages (from-to) | 650-657 |
| Number of pages | 8 |
| Journal | Rheumatology |
| Volume | 53 |
| Issue number | 4 |
| Early online date | 9 Dec 2013 |
| DOIs | |
| Publication status | Published - Apr 2014 |
Fingerprint
Keywords
- Africa
- Asia
- Europe
- HLA-B27 Antigen
- Humans
- Latin America
- North America
- Prevalence
- Spondylitis, Ankylosing
- World Health
- Spondyloarthropathies
- Epidemiology
- Systematic Review
Cite this
Global prevalence of ankylosing spondylitis. / Dean, Linda E.; Jones, Gareth T; MacDonald, Alan G; Downham, Christina; Sturrock, Roger D; Macfarlane, Gary J.
In: Rheumatology, Vol. 53, No. 4, 04.2014, p. 650-657.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Global prevalence of ankylosing spondylitis
AU - Dean, Linda E.
AU - Jones, Gareth T
AU - MacDonald, Alan G
AU - Downham, Christina
AU - Sturrock, Roger D
AU - Macfarlane, Gary J
N1 - Acknowledgements L.E.D. was supported by a UK Medical Research Council PhD studentship. Disclosure statement: G.T.J., R.D.S. and G.J.M. have received funding from AbbVie Pharmaceuticals and Pfizer for studies to estimate the prevalence of AS. No data from these studies were eligible for this review. All other authors have declared no conflicts of interest. Supplementary data Supplementary data are available at Rheumatology Online.
PY - 2014/4
Y1 - 2014/4
N2 - OBJECTIVES: For effective health care provision, knowledge of disease prevalence is paramount. There has been no systematic endeavour to establish continent-based AS estimates, however, prevalence is thought to vary by country and background HLA-B27 prevalence. This study aimed to estimate AS prevalence worldwide and to calculate the expected number of cases.METHODS: A systematic literature search was conducted. Prevalence data were extracted and used to calculate the mean prevalence by continent and the expected number of cases based on country-specific prevalence (or, if missing, the prevalence from neighbouring countries). A second estimate was made using the prevalence from countries with similar HLA-B27 prevalences if a country-specific prevalence estimate was not available.RESULTS: The mean AS prevalence per 10,000 (from 36 eligible studies) was 23.8 in Europe, 16.7 in Asia, 31.9 in North America, 10.2 in Latin America and 7.4 in Africa. Additional estimates, weighted by study size, were calculated as 18.6, 18.0 and 12.2 for Europe, Asia and Latin America, respectively. There were sufficient studies to estimate the number of cases in Europe and Asia, calculated to be 1.30-1.56 million and 4.63-4.98 million, respectively.CONCLUSION: This study represents the first systematic attempt to collate estimates of AS prevalence into a single continent-based estimate. In addition, the number of expected cases in Europe and Asia was estimated. Through reviewing the current literature, it is apparent that the continuing conduct of epidemiological studies of AS prevalence is of great importance, particularly as diagnostic capabilities improve and with the recent development of the criteria for axial SpA.
AB - OBJECTIVES: For effective health care provision, knowledge of disease prevalence is paramount. There has been no systematic endeavour to establish continent-based AS estimates, however, prevalence is thought to vary by country and background HLA-B27 prevalence. This study aimed to estimate AS prevalence worldwide and to calculate the expected number of cases.METHODS: A systematic literature search was conducted. Prevalence data were extracted and used to calculate the mean prevalence by continent and the expected number of cases based on country-specific prevalence (or, if missing, the prevalence from neighbouring countries). A second estimate was made using the prevalence from countries with similar HLA-B27 prevalences if a country-specific prevalence estimate was not available.RESULTS: The mean AS prevalence per 10,000 (from 36 eligible studies) was 23.8 in Europe, 16.7 in Asia, 31.9 in North America, 10.2 in Latin America and 7.4 in Africa. Additional estimates, weighted by study size, were calculated as 18.6, 18.0 and 12.2 for Europe, Asia and Latin America, respectively. There were sufficient studies to estimate the number of cases in Europe and Asia, calculated to be 1.30-1.56 million and 4.63-4.98 million, respectively.CONCLUSION: This study represents the first systematic attempt to collate estimates of AS prevalence into a single continent-based estimate. In addition, the number of expected cases in Europe and Asia was estimated. Through reviewing the current literature, it is apparent that the continuing conduct of epidemiological studies of AS prevalence is of great importance, particularly as diagnostic capabilities improve and with the recent development of the criteria for axial SpA.
KW - Africa
KW - Asia
KW - Europe
KW - HLA-B27 Antigen
KW - Humans
KW - Latin America
KW - North America
KW - Prevalence
KW - Spondylitis, Ankylosing
KW - World Health
KW - Spondyloarthropathies
KW - Epidemiology
KW - Systematic Review
U2 - 10.1093/rheumatology/ket387
DO - 10.1093/rheumatology/ket387
M3 - Article
C2 - 24324212
VL - 53
SP - 650
EP - 657
JO - Rheumatology
JF - Rheumatology
SN - 1462-0324
IS - 4
ER -